10
Apr

After a record-setting first quarter put billions in the pockets of drug developers, second class of biotech upstarts is scrambling to cash out on Wall Street before an increasingly shaky market shuts the door on life sciences IPOs.

…read more

Source: Three IPO hopefuls look to squeeze out $144M as biotech gets bearish

    

0 No comments